Novel Drug for Menopause Symptoms Passes Phase 3 Test : vimarsana.com

The novel NK3 receptor inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.

Related Keywords

United States , Americans , America , Genevieve Neal Perry , Richardj Santen , , Ht Alternatives , Endocrine Society , University Of North Carolina At Chapel Hill , University Of Virginia , North America , Like Frequency , North Carolina , African Americans , Menopause , Enopausal Syndrome , Headache , Hormone Replacement Therapy , Ostmenopausal Hormone Replacement Therapy , Rt , Adverse Effects , Ide Effects , Endocrine Therapy , Hormone Therapy , Patient Safety , Sleep Disorder ,